Genomma Lab Internacional, S.A.B. de C.V.

DB:GEKA Stock Report

Market Cap: €1.1b

Genomma Lab Internacional. de Past Earnings Performance

Past criteria checks 4/6

Genomma Lab Internacional. de has been growing earnings at an average annual rate of 6.2%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 6.7% per year. Genomma Lab Internacional. de's return on equity is 14.4%, and it has net margins of 9.2%.

Key information

6.2%

Earnings growth rate

7.9%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate6.7%
Return on equity14.4%
Net Margin9.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Genomma Lab Internacional. de makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:GEKA Revenue, expenses and earnings (MXN Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2417,4661,6037,3030
30 Jun 2416,7671,3137,0700
31 Mar 2416,4861,0456,7200
31 Dec 2316,4671,0856,8380
30 Sep 2317,0741,3926,9880
30 Jun 2317,0301,4217,0020
31 Mar 2316,9831,4086,9320
31 Dec 2216,8201,3896,9220
30 Sep 2216,7781,3597,1850
30 Jun 2216,4121,3537,0430
31 Mar 2215,9541,3286,8770
31 Dec 2115,4871,3086,5700
30 Sep 2114,8681,3526,1350
30 Jun 2114,3121,3685,8720
31 Mar 2114,0831,4165,7360
31 Dec 2013,8701,4045,6660
30 Sep 2013,6191,1795,8990
30 Jun 2013,2681,0035,8240
31 Mar 2012,9108865,8100
31 Dec 1912,7137505,8240
30 Sep 1912,6179355,8150
30 Jun 1912,2749255,7350
31 Mar 1911,9219865,6150
31 Dec 1811,7941,1095,5780
30 Sep 1811,5561,2425,2640
30 Jun 1811,9001,2495,3780
31 Mar 1811,8861,2185,4540
31 Dec 1712,0781,2795,6220
30 Sep 1711,8989586,2950
30 Jun 1711,7411,2126,3830
31 Mar 1711,669-1,6037,5510
31 Dec 1611,316-1,6817,4910
30 Sep 1611,287-3,4478,4380
30 Jun 1610,988-3,7598,3630
31 Mar 1611,125-8957,3250
31 Dec 1511,042-1,1377,3340
30 Sep 1511,2111,1095,7910
30 Jun 1511,9461,4105,8680
31 Mar 1511,8711,3965,7480
31 Dec 1411,5411,4325,5690
30 Sep 1412,3751,7765,5310
30 Jun 1412,0821,7665,4440
31 Mar 1411,7151,7755,2280

Quality Earnings: GEKA has high quality earnings.

Growing Profit Margin: GEKA's current net profit margins (9.2%) are higher than last year (8.2%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: GEKA's earnings have grown by 6.2% per year over the past 5 years.

Accelerating Growth: GEKA's earnings growth over the past year (15.1%) exceeds its 5-year average (6.2% per year).

Earnings vs Industry: GEKA earnings growth over the past year (15.1%) did not outperform the Pharmaceuticals industry 25.4%.

Return on Equity

High ROE: GEKA's Return on Equity (14.4%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/06 01:25
End of Day Share Price 2025/01/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Genomma Lab Internacional, S.A.B. de C.V. is covered by 16 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Antonio Hernandez Velez LeijaActinver Case de Bolsa, S.A. de C.V.
Benjamin TheurerBarclays
Miguel Ulloa SuárezBBVA Corporate and Investment Bank